Offering a fully non-invasive and precise approach to fluid management, the Starling Fluid Management Monitoring System is part of Baxter’s market-leading innovation in medication delivery. The Starling system advances efforts to shift treatment away from a one-size-fits-all approach towards individualized, patient-specific clinical decisions to help clinicians deliver the right therapy to the right patient, every time.
100% NON-INVASIVE FLUID MANAGEMENT
The Starling system empowers clinicians with the accurate, reliable and 100% non-invasive fluid management technology needed to dose fluids in accordance with individual patient response, which may help to improve health and economic outcomes.
Assessing whether fluid may help or harm a patient is a critical step in optimizing treatment. The Starling system provides a full hemodynamic profile within seconds to deliver meaningful insights that drive real-time clinical decision-making across the continuum of care, which includes Emergency Department, Intensive Care Unit, Operating Room and Rapid Response Team scenarios.
FLEXIBLE, ACCURATE TECHNOLOGY MEETS A DYNAMIC CLINICAL NEED
Healthcare professionals know that every patient has unique and constantly changing fluid management needs. Yet fluid monitoring technology has traditionally not provided the flexibility and rapid accuracy needed to account for these dynamic needs.
Using patented Bioreactance technology, the Starling system represents the latest advancements in hemodynamic monitoring, providing easy-to-use, non-invasive technology that delivers accurate and precise data that takes the guesswork out of fluid assessment.
ENHANCING CLINICAL AND ECONOMIC OUTCOMES
Proper fluid management may improve clinical outcomes and help reduce costs.1-3 Published data demonstrate the Starling system’s positive impact on improved patient outcomes and associated reductions in cost of care.1,3 The Starling system also aligns with compliance measures to the SEP-1 Quality Measure issued by the Centers for Medicare and Medicaid Services (CMS).
AN EXTENSIVELY VALIDATED TECHNOLOGY
- 500+ patients in published clinical studies
- Multiple clinical settings, including ICU, ED, OR, exercise lab and outpatient
- Comparative analyses against all major technologies, including Swan-Ganz, Pulse Contour, Doppler and Fick
- 100+ peer-reviewed publications
Rx Only. For safe and proper use of product mentioned herein, please refer to the Instructions for Use or Operator’s Manual.
Baxter, Starling and Bioreactance Technology are trademarks of Baxter International Inc. or its subsidiaries.